Reversible Neurological Adverse Reaction to Apixaban
Prescriptions for the novel oral anticoagulant factor Xa inhibitors (rivaroxaban, apixaban, edoxaban) have equalled or exceeded those for vitamin K antagonists in many clinical settings requiring chronic anticoagulation, and those of injectable heparins for deep vein thrombosis prophylaxis. The auth...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
SMC MEDIA SRL
2021-04-01
|
Series: | European Journal of Case Reports in Internal Medicine |
Subjects: | |
Online Access: | https://www.ejcrim.com/index.php/EJCRIM/article/view/1739 |
id |
doaj-19cf26e17f864e88a323b0abbebc468c |
---|---|
record_format |
Article |
spelling |
doaj-19cf26e17f864e88a323b0abbebc468c2021-04-19T16:13:43ZengSMC MEDIA SRLEuropean Journal of Case Reports in Internal Medicine2284-25942021-04-0110.12890/2021_0017391371Reversible Neurological Adverse Reaction to ApixabanEduardo Rodrigues Cernadas0Catarina Dionisio1Dalia Estevão2Leopoldina Vicente3Centro Hospitalar Universitário Cova da Beira, Covilhã, PortugalCentro Hospitalar Universitário Cova da Beira, Covilhã, PortugalCentro Hospitalar Universitário Cova da Beira, Covilhã, PortugalCentro Hospitalar Universitário Cova da Beira, Covilhã, PortugalPrescriptions for the novel oral anticoagulant factor Xa inhibitors (rivaroxaban, apixaban, edoxaban) have equalled or exceeded those for vitamin K antagonists in many clinical settings requiring chronic anticoagulation, and those of injectable heparins for deep vein thrombosis prophylaxis. The authors report the case of an 80-year-old woman followed by her cardiologist for permanent atrial fibrillation who was prescribed apixaban. Within a few days the patient developed neurological symptoms of imbalance and non-vertiginous dizziness, headache, confusion/disorientation and asthenia. Her symptoms began to resolve after the drug was stopped, with return to baseline function within 72 h. The plasma concentration of apixaban was 4 times higher than the laboratory upper limit of normal. Symptoms did not recur when the patient was switched to rivaroxaban therapy.https://www.ejcrim.com/index.php/EJCRIM/article/view/1739apixabanneurological symptomsadverse drug reaction |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Eduardo Rodrigues Cernadas Catarina Dionisio Dalia Estevão Leopoldina Vicente |
spellingShingle |
Eduardo Rodrigues Cernadas Catarina Dionisio Dalia Estevão Leopoldina Vicente Reversible Neurological Adverse Reaction to Apixaban European Journal of Case Reports in Internal Medicine apixaban neurological symptoms adverse drug reaction |
author_facet |
Eduardo Rodrigues Cernadas Catarina Dionisio Dalia Estevão Leopoldina Vicente |
author_sort |
Eduardo Rodrigues Cernadas |
title |
Reversible Neurological Adverse Reaction to Apixaban |
title_short |
Reversible Neurological Adverse Reaction to Apixaban |
title_full |
Reversible Neurological Adverse Reaction to Apixaban |
title_fullStr |
Reversible Neurological Adverse Reaction to Apixaban |
title_full_unstemmed |
Reversible Neurological Adverse Reaction to Apixaban |
title_sort |
reversible neurological adverse reaction to apixaban |
publisher |
SMC MEDIA SRL |
series |
European Journal of Case Reports in Internal Medicine |
issn |
2284-2594 |
publishDate |
2021-04-01 |
description |
Prescriptions for the novel oral anticoagulant factor Xa inhibitors (rivaroxaban, apixaban, edoxaban) have equalled or exceeded those for vitamin K antagonists in many clinical settings requiring chronic anticoagulation, and those of injectable heparins for deep vein thrombosis prophylaxis. The authors report the case of an 80-year-old woman followed by her cardiologist for permanent atrial fibrillation who was prescribed apixaban. Within a few days the patient developed neurological symptoms of imbalance and non-vertiginous dizziness, headache, confusion/disorientation and asthenia. Her symptoms began to resolve after the drug was stopped, with return to baseline function within 72 h. The plasma concentration of apixaban was 4 times higher than the laboratory upper limit of normal. Symptoms did not recur when the patient was switched to rivaroxaban therapy. |
topic |
apixaban neurological symptoms adverse drug reaction |
url |
https://www.ejcrim.com/index.php/EJCRIM/article/view/1739 |
work_keys_str_mv |
AT eduardorodriguescernadas reversibleneurologicaladversereactiontoapixaban AT catarinadionisio reversibleneurologicaladversereactiontoapixaban AT daliaestevao reversibleneurologicaladversereactiontoapixaban AT leopoldinavicente reversibleneurologicaladversereactiontoapixaban |
_version_ |
1721519143878918144 |